

---

# Propensity Scores: mixing & matching

Jonathan Alsop

Numerus Ltd

ROeS, 10 Sep 2013

**numerus**  
Discover Statistical Power

Numerus Ltd, UK and Europe | www.numerus-ltd.com | © Numerus Ltd 2011

---

## Background

- Propensity scores - method to **estimate treatment effect** when random assignment not feasible / possible (e.g. observational studies)
- Subjects with certain characteristics more likely to receive treatment than others.

*Are differences in outcome between treated & control subjects due to treatment OR differences on other characteristics?*

**numerus**  
Discover Statistical Power

Numerus Ltd, UK and Europe | www.numerus-ltd.com | © Numerus Ltd 2011

## Context

Do drugs/devices work in 'real-life' settings?

### FDA Sentinel Initiative

- 2007
- AE reporting from *100 million* patients

### EMA PROTECT

- 2009
- monitoring benefit-risk of medicines

### CPRD (NHS, UK)

*Effectiveness, but safety signals: rare & drug-drug*

numerus

## Nutshell

Compare treatment between groups who “looked similar” prior to treatment assignment

Groups selected/analysed based on PS:

*conditional probability* a subject would receive a certain treatment based on his/her **pre-treatment characteristics**

treated subject PS = control subject PS

➡ **observed covariates are controlled for**

*Create pseudo-randomised study*

numerus

## So who's to blame?



Rosenbaum and Rubin (1983) "The Central Role of the Propensity Score in Observational Studies for Casual Effects."

numerus

## Case study: PAH Registry

- Pulmonary arterial hypertension
- Progressive disease - narrowing of arteries
- Prevalence of 15-50 / million
- 20 - 50% dead < 3 years




## PAH Registry

---

### Is combination therapy better than monotherapy?

Outcome = time to death from diagnosis

Point of diagnosis (demography, disease severity)



numerus

## Step 1: Obtaining PS

---

Obtain PS for each subject from:

- Logistic regression
- Classification and Regression Tree Analysis
- Neural networks

Can be done blindly (i.e. before outcome examined)

numerus

## Obtaining PS

---

Using logistic regression to obtain PS:

- Kitchen sink approach: can have complicated model
- Consider including interactions and polynomial effects
- 100s of covariates considered (see Hd PS)

numerus

© Numerus 2013

## PS 'Philosophies'

---

- Expert-judged treatment drivers
- Covariates that:
  - just predict the treatment assignment
  - potentially related to the outcome
  - associated with both the treatment assignment & outcome



numerus

© Numerus 2013

## PAH Study: Obtaining PS

---

- N=173 patients with “Month 3” assessment
- Logistic regression (PROC GENMOD)
- Outcome: therapy type (mono=0, combo=1)
- Covariates:
  - Sex
  - Functional class
  - First line therapy (diagnosis)
  - Total Pulmonary Resistance (TPR) at Month 3
- Obtain predicted probability of combo (PS)

numerus

© 2013 Numerus, Inc. All rights reserved.

## Step 2: Can we match?

---



numerus

© 2013 Numerus, Inc. All rights reserved.

## Simple matching example

Match treated subjects PS with untreated subjects with same/similar PS, e.g. 1:1 match

Received treatment

0.259 0.54 0.63 0.90

A B C D

No treatment

1 2 3 4 5 6  
0.363 0.54 0.90 0.19 0.63 0.259


The unmatched subjects are discarded from the analysis

numerus

© Numerus 2013

## PS Overlap

How Much Overlap In The Propensity Scores Do We Want?



numerus

© Numerus 2013

## PS Overlap


Need **'substantial' overlap** between treated & control otherwise.....**significant loss of data / bias**

Often better to **match all treated patients**, then follow with analytical adjustments for residual imbalances in the covariates

*but see Baser 2007 – less weight on extreme PS*

numerus

## PAH Study: PS Overlap





## Step 3: How to match/analyse?

---



numerus

© 2013 Numerus Ltd

## What we really are aiming for...

---



numerus

© 2013 Numerus Ltd

## Methods

---

One or combination of the 4 main methods:

- Stratification
- Matching
- Regression adjustment
- Weighting (IPWT)

numerus


## Methods: Stratification

---

- PS used to stratify the subjects into homogenous subclasses (e.g. deciles, quintiles) with similar PS.
- Each stratum consists of similar # of subjects (*treated? controls?*)
- Check estimated treatment effect size in each strata

*e.g. PROC XXX with strata command*

numerus



## Methods: Matching

Treatment & control patients are matched on their PS

- Ratio treated:control (1:1, 1:n)
- With/without replacement (with has impact on analysis method)
- Caliper width (match vs. non-match)
  - PS diff.=0.00001 to 0.1 ;  $0.2 \times \text{SD} [\text{logit}(\text{PS})]$  ;  $0.6 \times \text{SD}(\text{PS})$
- Matching method:
  - Nearest neighbour (with replacement)
  - Greedy (nearest neighbour without replacement, sub-optimal)
  - Radius (nearest neighbours within caliper)
  - Overall distribution (*network flow theory*, optimal, PROC NETFLOW SAS/OR)
  - Kernel (local linear), Genetic,...etc!

SAS progs: Parsons (2004), Fraeman (2010),

<http://mayoresearch.mayo.edu/mayo/research/biostat/sasmacros.cfm>

**Adjust analyses for matches! e.g. paired t-test, stratified, GEE/multi-level**

numerus

## Matching: Checking covariate balance

- Propensity score dist.
- Standardized differences
- Compare covariate distributions (e.g. boxplots, q-q plots)
- Regression (e.g. ANOVA on covariate)



numerus

## Methods: Regression & IPWT

### Covariate/Regression adjustment

- PS is a covariate (cont. or cat.) in regression model

### Weighting (IPTW aka Inverse Probability of Treatment Weighted)

- patients are re-weighted in order to make them more representative of the population *e.g. PROC XXXX with weight command*
- weight: Treated=  $1/PS$ , Controls=  $1/(1-PS)$   
*e.g. treated subject with a 20% predicted probability =  
 4 × treated subjects with a 80% predicted probability*
- sensitive to outliers - truncation/trimming (e.g. at 5-95 pct)
- variance(tx effect) ideally take into account  $var(PS)$ 
  - bootstrap from PS model onwards

numerus

## Ok, so which method?

Combination of methods often used  
No method is deemed 'best'



*I vote for...*

*1<sup>st</sup> Greedy matching with covariate adjustment*

*2<sup>nd</sup> Stratification with covariate adjustment*


numerus

## PAH Study: Matching PS

- Standard Cox PH, time to death PROC PHREG on all pts
- Stratified 5 strata, PROC PHREG on all pts; strata option
- Matching PROC PHREG on sample matched pts ; strata option
  - Greedy, 1:2 combo:mono, max diff=0.1
- IPWT
  - PS weights PROC PHREG on all pts; weight option
  - with/without truncation truncated at 5.7 (90 pct)

*All: with/without covariates*

numerus



## Why Not Do 'Plain-Vanilla' Regression Instead?

Complicated PS model with interactions & polynomial terms



Simpler final model when PS is included

Rare events: PS analysis better than standard regression

Easier to check covariate balance

numerus

## Extensions

---

Apply propensity score in longitudinal studies

Construct time-dependent propensity score:

- sequential matching
- inverse-probability-of-treatment weighted (IPTW) estimator
- marginal structural models

High-Dimensional Propensity Score

- hundreds of possible treatment predictors

numerus

© 2013 Numerus Health Inc.

## The good...

---



- Intuitive (face value, but....?)
- Predicting treatment allocation interesting
- Analyse rare events
- PSM reduces bias of treatment comparisons
- More robust than regression
- Can check balancing assumptions easily
- Can check the overlap of multivariate covariate distributions in the control and treated groups

numerus

© 2013 Numerus Health Inc.

## The not so good...



- Larger variance of regression, data loss
- PS balance achieved?
- Assumes treatment constant within a patient **but see MSM**
- Biased if unobserved confounders exist (unlike rand<sup>n</sup>)
- Large sample required
- Pts within matched pairs aren't independent see Austin (2007)
- Appropriate variance estimation and CI calculation for PS analyses often omitted (bootstrapping required?)
- Handling of missing data not clear
- Use in generalised & non-linear models less well understood
- Applicability & representation cf. population

numerus

## PS analysis summary...



Useful *additional* tool, but *easy*?

Obtaining PS



Matching / analysis



*Trade-off precision vs. bias (but surely bias more important...?!)*

Future use:

Pharmacovigilance

Blinded combination of health databases (Rassen 2010)

Phase 3b/4 trials more easily undertaken / analysed?

Stratified medicine need large, multi-tx trials (observational)

numerus



## Recommended reading

**A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.** Austin P. *Statist. Med.* 2008; 27:2037–2049

**An Introduction to Implementing Propensity Score Matching With SAS®.** Fraeman, K. 2010. NESUG

**Analysis of Observational Health Care Data Using SAS.** Faries D, Leon A, Haro H, & Obenchain R. 2010

**High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.** Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. *Epidemiology.* 2009; 20(4):512-22

**Performing a 1:N Case-Control Match on Propensity Score.** Parsons L. 2004. SUGI-29

**Propensity Score Matching with Limited Overlap.** Baser O. *Economics Bulletin.* 2007; 9(8):1-8

**Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques.** Parsons L. 2001. SUGI-26

**Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases.** Rassen JA, Avorn MD and Schneeweiss S. *Pharmacoepidemiology and Drug Safety* 2010; 19: 848–857

**The central role of the propensity score in observational studies for causal effects.** R. Rosenbaum P, Rubin D. *Biometrika.* 1983; 70 (1): 41-55

numerus

Discover Statistical Power

Numerus LLC, UK and Europe | www.numerus-llc.com | © Numerus LLC 2011

# *Thank you!*

numerus

Discover Statistical Power

Numerus LLC, UK and Europe | www.numerus-llc.com | © Numerus LLC 2011

## Good PSM

---

- Matching based on variables that are accurately & reliably measured.
- Substantial overlap between groups on the PS.
- Adequately balance on covariates between groups.
- Adjusts for selection bias & minimizes group differences across many variables.
- It does not use only conveniently available covariates such as age and gender.
- Sensitivity analysis is a recommended part of the process
- Choosing variables and adjusting for propensity scores is based on logic, theory & empirical evidence

numerus

© 2013 Numerus, Inc. All rights reserved.

## Comparing PSM with Hard Matching

---

- PSM is more suitable when dealing with a large number of covariates whereas hard matching is more appropriate when dealing with a small number of covariates.
- Both methods control for observed covariates and do not account for bias resulting from the unobserved covariates that may affect whether a subject receives treatment or not.
- PSM and matching both produce similar results when matching on a small number of covariates.

numerus

© 2013 Numerus, Inc. All rights reserved.

## PS Overlap

What if Treated and Untreated groups overlap, but minimally?

- Not much help
- The info available to infer treatment effect will reside almost entirely in the few patients who overlap.
- Need to think hard about whether useful inferences will be possible.

numerus

## Step 4: Check Sensitivity

“How much hidden bias would have to be present to alter the study’s conclusions?”

Table 5: Representative results of sensitivity analysis\* on time from first visit to end-points SP and EDSS 4.0 and 6.0: how the magnitude of an unmeasured binary confounder might affect the propensity score-adjusted HRs of Table 4

End-point	HR <sup>†</sup>	P <sub>0</sub> -P <sub>1</sub> <sup>‡</sup>	Adjusted	
			HR	95% CI
SP	2	0.8	0.66	0.41–1.00
	4	0.4	0.67	0.42–1.02
	6	0.3	0.67	0.42–1.02
	8	0.2	0.69	0.44–1.06
EDSS 4.0	2	0.1	0.76	0.58–1.03
EDSS 6.0	2	0.1	0.65	0.41–1.03

\*This analysis assumes that: 1) the unmeasured confounder is binary; 2) the unmeasured confounder is independent of measured confounders; 3) there is no interaction between the unmeasured confounder and exposure; <sup>†</sup>Hypothetical HR of the unmeasured confounder on time to end-points; <sup>‡</sup>Differences in prevalence of the unmeasured confounder between IFNB-treated and controls. From Trajano *et al.*<sup>26</sup>

## Checking covariate balance

